Asset profile
Brolucizumab-Dbll
Monoclonal antibody
Evidence outlook
Approved: Age-Related Macular Degeneration
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
42 competitors in this universe: 11 direct rivals (same mechanism and indication), 11 same-class, 20 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Brolucizumab-Dbll: this drug | Approved | Monoclonal antibody | VEGF-A | ||
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | ||
| Pegaptanib (Macugen) | Approved | Small molecule | VEGF-A | ||
| Ranibizumab (Lucentis) | Approved | Monoclonal antibody | VEGF-A | ||
| ABBV-RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| CKD-701 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| HLX04-O | Phase 3 | Monoclonal antibody | VEGF-A | ||
| KSI-301 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| Surabgene Lomparvovec (ABBV-RGX-314) | Phase 3 | Gene therapy / editing | VEGF-A | ||
| Tarcocimab Tedromer | Phase 3 | Monoclonal antibody | VEGF-A | ||
| MW02 | Phase 2/3 | Monoclonal antibody | VEGF-A | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A |
…and 27 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.